NCT07397481CompletedPhase 4
Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients
Dose Prediction for Antihypertensive Medications in Cirrhotic Patients Using Simcyp Program: Applications in Clinical Practice
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
This was a prospective, open-label, randomized, parallel pilot clinical study conducted over 3 months on 50 Egyptian cirrhotic patients with arterial hypertension and portal hypertension, evaluating the real-world applicability of selected PBPK-guided dosing regimens. Patients were stratified according to Child-Pugh class (CP-A or CP-B) and randomly assigned to receive either nebivolol or carvedilol at doses corresponding to the closest commercially available strengths to Simcyp®-predicted doses. Clinical evaluation included serial blood pressure measurements, comprising systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate (HR). Doppler ultrasonographical assessment was performed to evaluate portal and hepatic hemodynamics, including portal vein diameter, portal vein velocity, congestion index, hepatic artery resistive index, and modified vascular liver index. Routine laboratory investigations were conducted to assess efficacy and safety and included liver function tests (serum albumin, total bilirubin, alanine aminotransferase \[ALT\], and aspartate aminotransferase \[AST\]), kidney function tests (serum creatinine and blood urea nitrogen \[BUN\]), and fasting blood glucose. Patients were followed on a monthly basis, with systematic documentation of adverse events throughout the study period.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 20 Jan 2026
- Start date
- 1 Mar 2024
- Primary completion date
- 1 Mar 2025
- Lead sponsor
- Kafrelsheikh University
- Diseases
- High blood pressure
- NCT number
- NCT07397481
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 40
- From 1 Mar 2024 to the primary completion date, 1 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking drugs that interact with antihypertensive drugs in the last two weeks
Other illness
- Patients with kidney disorder or dialysis
- Hypersensitivity to study medications
- Active cancer history in the last 2 years
Other
- Pregnancy
Who the study is looking for
- Age of patients \> 18 years.
- Diagnosed with cirrhosis
- Have cardiovascular disease(Hypertension )
- Presence of portal hypertension
- No history of variceal bleeding
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kafrelsheikh University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.